Moderna Inc. (MRNA) shares surged 5.49% in premarket trading on June 30, 2025, following the announcement of positive Phase 3 trial results for its experimental mRNA-based influenza vaccine.
Trial Results of Flu Vaccine
Moderna's experimental mRNA-based flu vaccine, mRNA-1010, demonstrated significant superiority over currently available influenza vaccines in a comprehensive Phase 3 trial involving over 40,000 adults aged 50 and above. The study revealed that Moderna’s shot was 26.6% more effective than standard competitor vaccines, with even stronger results among adults aged 65 and older, showing 27.4% greater efficacy.
Stock Performance of Moderna
MRNA stock demonstrated strong premarket momentum, gaining $1.49 to reach $28.65, representing a 5.49% increase from the previous close of $27.16. Despite this positive movement, Moderna shares remain under pressure for 2025, declining 34.68% year-to-date.
Outlook for Moderna
The positive flu vaccine data could serve as a catalyst for improved investor confidence as Moderna seeks to diversify its revenue streams beyond COVID-19 vaccines into broader respiratory and infectious disease markets. However, the company faces challenges including regulatory uncertainties and reduced COVID-19 vaccine demand.
The success of the experimental flu vaccine may restore investor interest in Moderna shares, which are facing challenges amid a general decline in vaccine demand and competition pressures.
